Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Receivables: 2016-2025

Historic Change in Receivables for Intellia Therapeutics (NTLA) over the last 9 years, with Sep 2025 value amounting to -$303,000.

  • Intellia Therapeutics' Change in Receivables rose 91.28% to -$303,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 7.07%. This contributed to the annual value of -$27.9 million for FY2024, which is 185.47% down from last year.
  • Per Intellia Therapeutics' latest filing, its Change in Receivables stood at -$303,000 for Q3 2025, which was down 135.69% from $849,000 recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Change in Receivables high stood at $30.0 million for Q4 2023, and its period low was -$24.1 million during Q2 2024.
  • For the 3-year period, Intellia Therapeutics' Change in Receivables averaged around $662,000, with its median value being $151,000 (2023).
  • As far as peak fluctuations go, Intellia Therapeutics' Change in Receivables surged by 11,850.98% in 2023, and later plummeted by 16,059.60% in 2024.
  • Over the past 5 years, Intellia Therapeutics' Change in Receivables (Quarterly) stood at -$460,000 in 2021, then surged by 44.57% to -$255,000 in 2022, then soared by 11,850.98% to $30.0 million in 2023, then tumbled by 101.12% to -$337,000 in 2024, then soared by 91.28% to -$303,000 in 2025.
  • Its Change in Receivables stands at -$303,000 for Q3 2025, versus $849,000 for Q2 2025 and $2.0 million for Q1 2025.